The OMERACT Vasculitis Study Group has been working on ways of measuring health-related quality of life in patients with ANCA-associated vasculitis (AAV). Focusing on the assessment of quality of life is important for inclusion in future clinical studies and allow for measurement of the effect of treatment on aspects of disease which are most important to patients. Patients with AAV have inflammation in the small blood vessels leading to involvement of a range of different body areas, for example the kidneys, lungs, and skin. Major progress has been made in the treatment of AAV, but patients often still suffer from ongoing disease activity or treatment side effects which have a negative impact on quality of life.

OMERACT Endorsed Core Set of Outcome Measures for Clinical Trials in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Screen Shot 2020-09-17 at 8.49.39 PM



Screen Shot 2020-09-17 at 9.03.33 PM

Peter Merkel:

Screen Shot 2020-09-17 at 9.16.48 PM

Haner Direskeneli:

Screen Shot 2020-09-17 at 9.19.27 PM

Alfred Mahr:


Susan Ashdown
Maarten Boers
Annelies Boonen
George Casey
Peter Cronholm
David Cuthbertson
Jill Dawson
Haner Direskeneli

Ebony Easley
John Farrar
Don Gebhart
Katherine Kellom
Tanaz Kermani
Jeffery Krischer
Gerogia Lanier
Raashid Luqmani
Alfred Mahr

Carol McAlear
Nataliya Milman
Jacqueline Peck
Joanna Robson
Judy Shea
Bev Shea
Antoine Sreih
Gunnar Tomasson
Peter Tugwell